With approval received in the US, Europe and China, Carl Zeiss Meditec AG is expanding the applications of its Intrabeam radiotherapy system from primarily breast cancer to include additional cancer treatments. The Zeiss Intrabeam intraoperative radiotherapy system. Courtesy of Business Wire. Over the past 14 years, Intrabeam has been used to treat 8000 patients around the world, predominantly for breast cancer, Zeiss Meditec said. Unlike traditional radiotherapy, Intrabeam brings a low-energy x-ray source into direct contact with the tumor or tumor margin to irradiate the affected tissue more precisely, reducing irradiation to nearby healthy tissue and organs. Because it uses low x-ray energy (50 kV), the tool doesn't require complex radiation shielding and is suitable for mobile use, the company said. "We now also offer patented radiation technology for patients with skin or gastrointestinal tumors, or with metastases in the spine area," said Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG. For more information, visit: www.meditec.zeiss.com